CXCL16 and soft tissue sarcoma: Similarly, glycolytic CAFs (glyCAFs) in soft tissue sarcomas create an immunosuppressive niche by producing CXCL16, which establishes a physical and chemotactic barrier to CD8+ T cell infiltration [123].